Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VNN1 | O95497 | 9/20 | 0.39 |
| ▸ | IKBKB | O14920 | 1/20 | 0.34 |
| ▸ | CHUK | O15111 | 1/20 | 0.34 |
| ▸ | IKBKG | Q9Y6K9 | 1/20 | 0.34 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.34 |
| ▸ | ATR | Q13535 | 1/20 | 0.33 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.33 |
| ▸ | CDK1 | P06493 | 3/20 | 0.33 |
| ▸ | CDK2 | P24941 | 3/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.32 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.32 |
| ▸ | ITGAL | P20701 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10166405 | 0.94 | IKBKB (0.38) | IKBKBCHUKIKBKGATRCDK1 | |
| SCHEMBL1685118 | 0.86 | MAPKAPK5 (0.44) | VNN1IKBKBCHUKIKBKGPDK2 | |
| SCHEMBL10166425 | 0.85 | ALDH1A1 (0.41) | MAPKAPK5 | |
| SCHEMBL10166023 | 0.84 | CSF1R (0.39) | ATRMAPKAPK5JAK2PIK3CAMTOR | |
| SCHEMBL10166356 | 0.84 | L3MBTL3 (0.42) | IKBKBCHUKIKBKGPIK3CAMTOR | |
| SCHEMBL10166412 | 0.84 | L3MBTL3 (0.37) | IKBKBCHUKIKBKGJAK2PIK3CA | |
| SCHEMBL10166351 | 0.84 | MAPKAPK5 (0.43) | MAPKAPK5JAK2 | |
| SCHEMBL10166430 | 0.83 | ADRA1A (0.40) | IKBKBCHUKIKBKGJAK2 | |
| SCHEMBL10165787 | 0.83 | FYN (0.37) | MAPKAPK5CDK1CDK2 | |
| SCHEMBL10166437 | 0.83 | CCND1 (0.37) | MAPKAPK5PIK3CAMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120010206-A1 | IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS N. V. (BE) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010206-A1 | IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | COL2A1, MMP1, COL1A1 | VNN1 775/4885IKBKB 135/4885CHUK 235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.